Article
Oncology
Benjamin M. Ellingson, John Sampson, Achal Singh Achrol, Manish K. Aghi, Krystof Bankiewicz, Chencai Wang, Martin Bexon, Steven Brem, Andrew Brenner, Sajeel Chowdhary, John R. Floyd, Seunggu Han, Santosh Kesari, Dina Randazzo, Michael A. Vogelbaum, Frank Vrionis, Miroslaw Zabek, Nicholas Butowski, Melissa Coello, Nina Merchant, Fahar Merchant
Summary: The study compared different neuro-oncology criteria in an immunotherapy trial for recurrent glioblastoma and found a strong correlation between PFS and OS using mRANO, while iRANO required confirmation of progression 3 months later, resulting in more than half of the patients being censored.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Sue Zhang, Kathryn Regan, Julian Najera, Mark W. Grinstaff, Meenal Datta, Hadi T. Nia
Summary: Cancer initiation and progression lead to significant changes in the microenvironment at the interface between healthy and malignant tissue, known as the peritumor. The peritumor is characterized by unique physical and immune attributes, which contribute to tumor progression through interconnected mechanical signaling and immune activity. Understanding and targeting the biomarkers and therapeutic targets in the peritumor is crucial for future cancer research and clinical advancements, particularly in overcoming resistance to immunotherapy.
Review
Pharmacology & Pharmacy
Chengming Chen, Zhaoyang Wang, Weiming Yan, Yanyan Lan, Xiaolong Yan, Tian Li, Jing Han
Summary: In the treatment of diabetic macular edema, the combination of anti-VEGF and ocular corticosteroids has a significant advantage within the first 3 months. However, as the treatment cycle prolongs, the effect of combination therapy is no better than monotherapy, and the side effects are more severe.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Oncology
Manpreet Kaur, Gabriel Cassinelli Petersen, Leon Jekel, Marc von Reppert, Sunitha Varghese, Irene Dixe de Oliveira Santo, Arman Avesta, Sanjay Aneja, Antonio Omuro, Veronica Chiang, Mariam Aboian
Summary: Peritumoral edema can significantly affect the neurological symptoms in patients with brain metastases. This study used PACS-based volume measurement to track edema changes and found that it may help predict treatment outcome. The study also discovered that the changes in edema volume can differ from the changes in contrast-enhancing lesion size, and this incongruence may be linked to lesion progression.
Article
Clinical Neurology
Stephen G. Bowden, Christian Lopez G. Ramos, Barry Cheaney II, Emma Richie, Nasser K. Yaghi, Daniel N. Munger, David J. Mazur-Hart, Hao Tan, Matthew D. Wood, Justin S. Cetas, Aclan Dogan, Ahmed M. Raslan, Seunggu J. Han
Summary: It is not known how steroids affect the improvement of focal neurological deficits in patients with brain metastases before surgery, and whether such improvement can predict long-term recovery of neurological function. This study aimed to determine the rate of improvement in focal deficits with preoperative corticosteroids and its predictive value for postoperative recovery in brain metastasis patients.
Article
Biochemistry & Molecular Biology
Yuhan Gu, Yuanyuan Guo, Na Gao, Yan Fang, Chen Xu, Guiming Hu, Mengxue Guo, Yaxing Ma, Yunfei Zhang, Jun Zhou, Yanlin Luo, Haifeng Zhang, Qiang Wen, Hailing Qiao
Summary: The proteomic characterization of the peritumor microenvironment (PME) in hepatocellular carcinoma (HCC) revealed significant differences between the occurrence and progression of HCC, with immunity playing a central role in occurrence and inflammation, angiogenesis, and metabolism being critical in progression.
Article
Pharmacology & Pharmacy
Amina Rezkallah, Laurent Kodjikian, Aymeric Barbarroux, Corentin Laventure, Antoine Motreff, Samuel Chacun, Frederic Matonti, Philippe Denis, Thibaud Mathis
Summary: This study evaluated the intraocular pressure (IOP) response following dexamethasone implant (DEX-I) injection in eyes with a history of conventional filtering surgery or microinvasive glaucoma surgery (MIGS). It found that eyes with previous effective bleb therapy had better IOP control after DEX-I injections and mostly did not require additional IOP-lowering therapy or surgery.
Article
Clinical Neurology
Li Xiang, Li-Hua Sun, Bin Liu, Long-Sheng Wang, Xi-Jun Gong, Ju Qiu, Ya-Qiong Ge, Wen-Jun Yao, Kang-Chen Gu
Summary: This study aimed to analyze the permeability of intra- and peri-meningiomas regions and compare the microvascular permeability between peritumoral brain edema (PTBE) and non-PTBE using DCE-MRI. Results showed that tumor size and V-p were associated with PTBE in patients with meningiomas.
EUROPEAN NEUROLOGY
(2021)
Article
Chemistry, Multidisciplinary
Luyao Wang, Chunyuan Gan, Hongyan Sun, Lin Feng
Summary: Micro-nano-robots have potential for targeted drug delivery, but few studies have allowed them to move against blood flow and penetrate endothelial cells. Inspired by the behavior of herring schools and leukocytes, magnetic nanoparticles can be assembled into vortex-like swarms under an electromagnetic field, enabling them to move upstream and penetrate intercellular gaps for targeted drug delivery. These miniature nanorobots can be reshaped and reconfigured to adapt to different circulatory environments, providing new solutions for biomedical applications.
Article
Oncology
Xin Chen, Mary Jane Lim-Fat, Lei Qin, Angie Li, Annie Bryant, Camden P. Bay, Lu Gao, Nityanand Miskin, Zaiyi Liu, J. Bryan Iorgulescu, Xiaoyin Xu, David A. Reardon, Geoffrey S. Young
Summary: The study compared the response assessment of GBM patients on ICB using iRANO and RANO criteria, showing high concordance in assessing progressive disease within 6 months of treatment initiation.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Yannick Suter, Urspeter Knecht, Waldo Valenzuela, Michelle Notter, Ekkehard Hewer, Philippe Schucht, Roland Wiest, Mauricio Reyes
Summary: This dataset provides longitudinal MRI data of Glioblastoma patients, including expert ratings and rationales for selected follow-up studies, as well as pathology information and survival time for some patients. The dataset also includes segmentations from automated tools and radiomic features, which can be used for radiomics research, development and validation of automated segmentation methods, and studies on response assessment.
Article
Medicine, General & Internal
Dino Ferracci, Thibaud Mathis, Antoine Gavoille, Mathieu Gerfaud-Valentin, Arthur Bert, Meriem Hafidi, Philippe Denis, Olivier Loria, Laurent Kodjikian, Pascal Seve
Summary: The purpose of this study was to report the progression of patients initially treated with corticosteroids for birdshot chorioretinopathy (BSCR). A total of 39 BSCR patients were included in the study and followed up for =1 year. The study found that prolonged corticosteroid therapy resulted in inflammation control in 50% of BSCR patients, with low doses of cortisone (<5 mg/day) being sufficient to maintain this control.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Thibaud Mathis, Maxence Papegaey, Cecile Ricard, Amina Rezkallah, Frederic Matonti, Aditya Sudhalkar, Cristina Vartin, Corinne Dot, Laurent Kodjikian
Summary: In this study, the functional and anatomical efficacy of the fluocinolone acetonide (FAc) implant in treating chronic diabetic macular edema (DME) was evaluated. The results showed that the FAc implant was effective and safe in patients with chronic DME who had previously received other treatments.
Review
Medicine, General & Internal
Michal Orski, Maciej Gawecki
Summary: Irvine-Gass syndrome is a common complication following cataract surgery, causing macular edema. While most cases of macular edema are benign, refractory cases may deteriorate visual function. There is currently no definitive treatment guideline, but topical non-steroidal anti-inflammatory drugs are recommended as first-line therapy, with invasive procedures reserved for prolonged or refractory cases.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Ophthalmology
Anne-Catherine Chapelle, Jean-Marie Rakic, Gordon T. Plant
Summary: The purpose of this study was to investigate the frequency and characteristics of intraretinal and subretinal fluid in nonarteritic anterior ischemic optic neuropathy (NAAION) and its influence on visual deficit and optic nerve fiber/ganglion cell loss. The study found that subretinal fluid is found in a high proportion of NAAION cases, but visual function remains largely stable after onset, and corticosteroid intake at presentation does not affect visual recovery or the timing of tissue edema absorption.
Letter
Oncology
Mei-Yin C. Polley, Thierry Gorlia, Andy B. Lassman, Martin J. van den Bent
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Julie J. Miller, L. Nicolas Gonzalez Castro, Samuel McBrayer, Michael Weller, Timothy Cloughesy, Jana Portnow, Ovidiu Andronesi, Jill S. Barnholtz-Sloan, Brigitta G. Baumert, Mitchell S. Berger, Wenya Linda Bi, Ranjit Bindra, Daniel P. Cahill, Susan M. Chang, Joseph F. Costello, Craig Horbinski, Raymond Y. Huang, Robert B. Jenkins, Keith L. Ligon, Ingo K. Mellinghoff, L. Burt Nabors, Michael Platten, David A. Reardon, Diana D. Shi, David Schiff, Wolfgang Wick, Hai Yan, Andreas von Deimling, Martin van den Bent, William G. Kaelin, Patrick Y. Wen
Summary: This article discusses the diagnosis and management of IDH-mutant gliomas, as well as new treatment methods and future research directions.
Article
Clinical Neurology
Katharina Seystahl, Juliane Schweizer, Mira Katan, Sung Ju Weber, Alessia Hug, Miriam Wanner, Andreas R. Luft, Sabine Rohrmann, Susanne Wegener, Michael Weller
Summary: Cancer is not a risk factor for stroke-associated infections in stroke patients. The incidence, characteristics, and treatment of infections did not differ significantly between stroke patients with and without cancer. However, both cancer and stroke-associated infections were associated with in-hospital mortality.
NEURO-ONCOLOGY PRACTICE
(2023)
Article
Oncology
Anna M. Di Giacomo, Maximilian J. Mair, Michele Ceccarelli, Andrea Anichini, Ramy Ibrahim, Michael Weller, Michael Lahn, Alexander M. M. Eggermont, Bernard Fox, Michele Maio
Summary: The conditions that promote immunotherapy responses in primary or secondary brain malignancies were discussed during the V Siena Immuno-Oncology (IO) Think Tank meeting in 2021. Important publications in 2021 and 2022 have reinforced the core elements of these discussions. While current immunotherapies have failed to benefit patients with primary brain tumors like glioblastoma, they have shown positive responses in brain metastases. The differences between these conditions seem to be influenced by intrinsic and extrinsic factors, such as driver mutations, the blood-brain barrier, and the immune suppressive microenvironment. Future therapeutic interventions may focus on rebalancing the immune cell population to enable better responses to current and future immunotherapies.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Corinna Seliger, Felix Boakye Oppong, Florence Lefranc, Olivier Chinot, Roger Stupp, Burt Nabors, Thierry Gorlia, Michael Weller, EORTC Brain Tumor Group
Summary: Depressive symptoms are common in glioblastoma patients, but they are often not treated with antidepressants. Limited evidence suggests that the use of antidepressants is not significantly associated with progression-free or overall survival in glioblastoma patients. However, using antidepressants at the start of maintenance cycle 4 is significantly associated with worse overall survival. Antidepressant use is not significantly associated with seizures, cognitive changes, or fatigue, except for an increase in fatigue during maintenance treatment. Confirmation and further study are needed to assess the impact of antidepressant use on the survival of glioblastoma patients. Prospective trials should evaluate the efficacy, side effects, and outcomes of antidepressant treatment in glioblastoma.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai, Levi van Hijfte, Nastaran Barin, Iris de Heer, Wouter Coppieters, Thierry P. P. van den Bosch, Anne Bolleboom, Zhenyu Gao, Arnaud J. P. E. Vincent, Latifa Karim, Manon Deckers, Martin J. B. Taphoorn, Melissa Kerkhof, Astrid Weyerbrock, Marc Sanson, Ann Hoeben, Slavka Lukacova, Giuseppe Lombardi, Sieger Leenstra, Monique Hanse, Ruth E. M. Fleischeuer, Colin Watts, Nicos Angelopoulos, Thierry Gorlia, Vassilis Golfinopoulos, Vincent Bours, Martin J. van den Bent, Pierre A. Robe, Pim J. French
Summary: A better understanding of the transcriptional evolution of IDH-wild-type glioblastoma is crucial for optimizing treatment. Through RNA sequencing, this study demonstrates that glioblastomas mainly evolve through microenvironmental reorganization rather than molecular evolution of tumor cells. The changes in tumor composition over time, including alterations in neuron and oligodendrocyte marker genes and an increase in tumor-associated macrophages, are confirmed by single-cell RNA-seq and immunohistochemistry.
Article
Clinical Neurology
Pim B. van der Meer, Linda Dirven, Marta Fiocco, Maaike J. Vos, Mathilde C. M. Kouwenhoven, Martin J. van den Bent, Martin J. B. Taphoorn, Johan A. F. Koekkoek
Summary: This study aimed to evaluate the effectiveness of levetiracetam combined with valproic acid and clobazam compared with other triple therapy combinations in patients with glioma. The results showed that there were no significant differences in treatment failure rate, uncontrolled seizure rate, adverse effects rate, and recurrent seizure rate between levetiracetam combined with valproic acid and clobazam and other triple therapy combinations.
Article
Medicine, General & Internal
Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust-Katz, Liam Welsh, Warren P. Mason, Francois Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F. Hottinger, Yoshiki Arakawa, Juan M. Sepulveda, Wolfgang Wick, Riccardo Soffietti, James R. Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth A. Maher, Steven Schoenfeld, Dan Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy
Summary: In a phase 3 trial, vorasidenib showed significant improvement in progression-free survival and delay in the time to the next intervention for patients with grade 2 IDH-mutant glioma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Clinical Neurology
M. J. van den Bent
Summary: This paper reviews the 30-year development of low-grade gliomas, including changes in diagnostics with the incorporation of 1p/19q and IDH mutations, improved surgical techniques, and improved delivery of radiotherapy and chemotherapy. Recently, the better understanding of altered cellular processes has led to the development of novel drugs that may completely alter the management of patients early in their disease.
REVUE NEUROLOGIQUE
(2023)
Article
Oncology
Tobias Kessler, Daniel Schrimpf, Laura Doerner, Ling Hai, Leon D. Kaulen, Jakob Ito, Martin van den Bent, Martin Taphoorn, Alba A. Brandes, Ahmed Idbaih, Julien Domont, Paul M. Clement, Mario Campone, Martin Bendszus, Andreas von Deimling, Felix Sahm, Michael Platten, Wolfgang Wick, Antje Wick
Summary: The EORTC-26101 study investigated the efficacy of combination therapy with bevacizumab and lomustine versus lomustine alone in progressive glioblastoma. Molecular data from DNA methylation arrays and panel sequencing were analyzed to assess prognostic biomarkers. The study found that MGMT promoter methylation and RTK1 classifier assignment were prognostic factors, while NF1 mutation may predict response to bevacizumab treatment.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Philipp Karschnia, Jorg Dietrich, Francesco Bruno, Antonio Dono, Stephanie T. Juenger, Nico Teske, Jacob S. Young, Tommaso Sciortino, Levin Haeni, Martin van den Bent, Michael Weller, Michael A. Vogelbaum, Ramin A. Morshed, Alexander F. Haddad, Annette M. Molinaro, Nitin Tandon, Juergen Beck, Oliver Schnell, Lorenzo Bello, Shawn Hervey-Jumper, Niklas Thon, Stefan J. Grau, Yoshua Esquenazi, Roberta Ruda, Susan M. Chang, Mitchel S. Berger, Daniel P. Cahill, Joerg-Christian Tonn
Summary: The absence of contrast enhancement in glioblastomas characterizes a less aggressive clinical phenotype, with smaller postoperative tumor volumes associated with more favorable outcomes. Maximal resection of non-CE tumors has prognostic implications and leads to a better outcome compared to lesion biopsy. Patients with non-CE glioblastoma have a more favorable clinical profile and superior outcome when compared to those with CE glioblastoma.
Article
Oncology
Karin A. van Garderen, Wies R. Vallentgoed, Anna Lavrova, Johanna M. Niers, Wendy W. J. de Leng, Youri Hoogstrate, Iris de Heer, Bauke Ylstra, Erik van Dijk, Stefan Klein, Kaspar Draaisma, Pierre A. J. T. Robe, Roel G. W. Verhaak, Bart A. Westerman, Pim J. French, Martin J. van den Bent, Mathilde C. M. Kouwenhoven, Johan M. Kros, Pieter Wesseling, Marion Smits
Summary: The T2-FLAIR mismatch sign is correlated with microcystic change in IDH-mutant astrocytomas, favorable prognosis, and Grade 2 tumors.
NEURO-ONCOLOGY ADVANCES
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wouter H. T. Teunissen, Anna Lavrova, Martin van den Bent, Anouk van der Hoorn, Esther A. H. Warnert, Marion Smits
Summary: This study investigates the correlation and diagnostic accuracy of quantitative cerebral blood flow and non-quantitative perfusion weighted imaging measurements in brain tumour surveillance using arterial spin labelling MRI. The results show that there is a high correlation between ASL-PWI ratios and ASL-CBF ratios and their diagnostic accuracy is comparable. Therefore, quantification of ASL-CBF can be omitted in these patients and visual assessment provides the same diagnostic accuracy as quantitative measurements.
EUROPEAN RADIOLOGY
(2023)
Article
Nutrition & Dietetics
Chun Sing Lam, Rong Hua, Yu Kang Wu, Ho Kee Koon, Keary Rui Zhou, Herbert Ho-Fung Loong, Vincent Chi-Ho Chung, Yin Ting Cheung
Summary: This study investigated the potential supplement-drug interactions involving the hepatic system and their associations with liver diseases among cancer patients. The results showed that approximately one-third of cancer patients who used supplements had a risk of potential interactions, but no significant association was observed between the use of these combinations and subsequent liver diseases.
CLINICAL NUTRITION ESPEN
(2023)